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But anyway the cart’s still there today.
I. A. Krylov, “Swan, Pike and Crawfish”
Studies of blood–biomaterial interactions can be traced
back more than a century. Surprisingly little progress has
been made during that time, either in terms of understanding
what goes on at the surface of materials that come into con-
tact with blood, or improving the properties of these surfa-
ces, prompting the quote from a famous fable as a parable
for the unsatisfactory state of affairs: all existing artificial
materials that come into contact with blood induce adverse
reactions such as thrombosis and inflammation.
The reliance of clinical practice on artificial materials in
implants and other devices continues to increase, and so does
the success with which implants and other devices help save
and improve patients’ lives. Underlying this progress is the
ability of clinicians to therapeutically manage the adverse
reactions caused by biomaterials rather than the improve-
ments of the materials themselves. In an effort to correct this
imbalance, we initiated a number of activities, including the
BloodSurf meeting that took place in 2014 in Frejus (74th
International IUVSTA Workshop on Blood–Biomaterial
Interactions: Surface Analysis meets Blood Compatibility,
http://www.vide.org/bloodsurf) and this In Focus collection
dedicated to the subject. An impressive range of topics is
covered here in the form of experimental papers, reviews,
and opinion pieces.
As protein adsorption and platelet activation at biomate-
rial surfaces are still considered central to the development
of adverse reactions, both feature prominently in several
papers. In this context, the report of Cornelius et al.1 on the
interaction of lipoproteins with bare and polyethylene
glycol-modified polyurethane surfaces can be highlighted, as
well as the two reports pointing to differences in plasma
protein adsorption and activation at different surfaces.2,9
Szott et al.2 and Gupta et al.3 also report differences in plate-
let activation between different surfaces. The two latter stud-
ies contribute to the growing body of evidence that platelet
spreading may not be representative of other activation phe-
nomena. Endothelialization of a vascular implant (a heart
valve prosthetic) is considered by Ghanbari et al.4 Testing
and screening approaches are discussed in their own right
and as a part of larger, systematic studies. The importance of
fresh blood in hemocompatibility testing is revisited by Blok
et al.5 Another important topic—that of biomaterials for pla-
telet storage—is raised by Farrugia et al.6 Current conditions
of platelet storage are utterly unsatisfactory due to limited
duration and the requirement for relatively high tempera-
tures, which contribute to the risk of bacterial contamination.
Jung and Braune7 discuss principles of thrombogenicity and
hemocompatibility testing, emphasizing that future studies
have to show which of the in vitro test assays has predictive
value for thrombotic processes at implant surfaces. Some
fundamental aspects of the bio/non-bio interfaces relevant to
various types of implants (not only vascular) are discussed
by Reviakine.8
The practitioners of the field of biological surfaces and
interfaces are uniquely poised for advancing hemocompati-
bility research through their ability to bridge disciplines. We
hope that this In Focus collection becomes a stepping stone
toward further progress.
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